NASDAQ:AEZS Aeterna Zentaris (AEZS) Stock Forecast, Price & News $2.78 0.00 (0.00%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$2.75▼$2.8250-Day Range$2.45▼$3.2352-Week Range$2.32▼$8.63Volume9,188 shsAverage Volume14,058 shsMarket Capitalization$13.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aeterna Zentaris MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.77Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.41) to ($2.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.43 out of 5 starsMedical Sector945th out of 1,006 stocksPharmaceutical Preparations Industry469th out of 492 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Aeterna Zentaris. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.69% of the float of Aeterna Zentaris has been sold short.Short Interest Ratio / Days to CoverAeterna Zentaris has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Aeterna Zentaris has recently decreased by 14.36%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAeterna Zentaris does not currently pay a dividend.Dividend GrowthAeterna Zentaris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AEZS. Previous Next 2.1 News and Social Media Coverage News SentimentAeterna Zentaris has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aeterna Zentaris this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aeterna Zentaris insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Aeterna Zentaris is held by insiders.Percentage Held by InstitutionsOnly 0.60% of the stock of Aeterna Zentaris is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aeterna Zentaris are expected to grow in the coming year, from ($3.41) to ($2.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aeterna Zentaris is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aeterna Zentaris is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAeterna Zentaris has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aeterna Zentaris (NASDAQ:AEZS) StockÆterna Zentaris, Inc. is a specialty biopharmaceutical company, which engages in the development and commercialization of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.Read More Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Email Address AEZS Stock News HeadlinesMay 31, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Aeterna Zentaris (NASDAQ:AEZS)May 30, 2023 | americanbankingnews.comShort Interest in Aeterna Zentaris Inc. (NASDAQ:AEZS) Decreases By 14.4%June 1, 2023 | Behind the Markets (Ad)AI Creates New Cancer Drug - In Just 30 Days!On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...May 26, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc down on Friday (AEZS)May 23, 2023 | americanbankingnews.comAeterna Zentaris (NASDAQ:AEZS) Receives New Coverage from Analysts at StockNews.comMay 17, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc down on Tuesday (AEZS)May 15, 2023 | finance.yahoo.comAeterna Zentaris Announces Virtual 2023 Meeting of ShareholdersMay 15, 2023 | americanbankingnews.comAeterna Zentaris (NASDAQ:AEZS) Coverage Initiated at StockNews.comJune 1, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 14, 2023 | americanbankingnews.comAeterna Zentaris Inc. (NASDAQ:AEZS) Sees Significant Increase in Short InterestMay 12, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Aeterna Zentaris (AEZS)May 10, 2023 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Reports First Quarter 2023 Financial ResultsMay 9, 2023 | finance.yahoo.comAeterna Zentaris Reports First Quarter 2023 Financial ResultsMay 1, 2023 | americanbankingnews.comComparing Addex Therapeutics (NASDAQ:ADXN) & Aeterna Zentaris (NASDAQ:AEZS)April 29, 2023 | americanbankingnews.comAeterna Zentaris (NASDAQ:AEZS) Now Covered by StockNews.comApril 27, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc down on Wednesday (AEZS)April 22, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Aeterna Zentaris (NASDAQ:AEZS)April 20, 2023 | americanbankingnews.comHead-To-Head Review: Homology Medicines (NASDAQ:FIXX) versus Aeterna Zentaris (NASDAQ:AEZS)April 6, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc up on Thursday (AEZS)April 6, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc up on Wednesday (AEZS)April 6, 2023 | finance.yahoo.comAeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone DrugApril 5, 2023 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Provides Update on Macrilen (Macimorelin), Reiterates Advancement of Pediatric DETECT TrialApril 5, 2023 | finance.yahoo.comAeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT TrialApril 1, 2023 | americanbankingnews.comAeterna Zentaris Inc. (NASDAQ:AEZS) Sees Large Drop in Short InterestMarch 31, 2023 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Aeterna Zentaris (NASDAQ:AEZS)March 31, 2023 | americanbankingnews.comHC Wainwright Weighs in on Aeterna Zentaris Inc.'s Q1 2024 Earnings (NASDAQ:AEZS)March 30, 2023 | americanbankingnews.comBrokers Issue Forecasts for Aeterna Zentaris Inc.'s Q1 2023 Earnings (NASDAQ:AEZS)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Email Address AEZS Company Calendar Last Earnings3/23/2023Today5/31/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AEZS CUSIPN/A CIK1113423 Webwww.zentaris.com Phone(418) 652-8525Fax418-948-9191Employees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,730,000.00 Net MarginsN/A Pretax Margin-389.41% Return on Equity-37.47% Return on Assets-26.03% Debt Debt-to-Equity RatioN/A Current Ratio7.88 Quick Ratio7.85 Sales & Book Value Annual Sales$5.64 million Price / Sales2.39 Cash FlowN/A Price / Cash FlowN/A Book Value$6.43 per share Price / Book0.43Miscellaneous Outstanding Shares4,860,000Free Float4,851,000Market Cap$13.49 million OptionableOptionable Beta1.38 Social Links Key ExecutivesKlaus Wolfgang PauliniPresident, Chief Executive Officer & DirectorGiuliano La FrattaChief Financial Officer & Senior Vice PresidentMichael TeifelChief Scientific Officer & Senior Vice PresidentNicola AmmerChief Medical Officer & Senior Vice PresidentPatricia ZahnDirector-Administrative Services & Human ResourcesKey CompetitorsUniverse PharmaceuticalsNYSE:UPCApexigenNASDAQ:APGNAkari TherapeuticsNASDAQ:AKTXBio-PathNASDAQ:BPTHVirios TherapeuticsNASDAQ:VIRIView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPSold 180,000 shares on 5/16/2023Ownership: 0.000%Group One Trading L.P.Sold 375,200 shares on 5/12/2023Ownership: 0.000%View All Institutional Transactions AEZS Stock - Frequently Asked Questions Should I buy or sell Aeterna Zentaris stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AEZS shares. View AEZS analyst ratings or view top-rated stocks. How have AEZS shares performed in 2023? Aeterna Zentaris' stock was trading at $3.18 at the start of the year. Since then, AEZS shares have decreased by 12.7% and is now trading at $2.7750. View the best growth stocks for 2023 here. Are investors shorting Aeterna Zentaris? Aeterna Zentaris saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 81,700 shares, a decrease of 14.4% from the April 30th total of 95,400 shares. Based on an average daily volume of 15,800 shares, the short-interest ratio is presently 5.2 days. Currently, 1.7% of the company's shares are sold short. View Aeterna Zentaris' Short Interest. When is Aeterna Zentaris' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our AEZS earnings forecast. How were Aeterna Zentaris' earnings last quarter? Aeterna Zentaris Inc. (NASDAQ:AEZS) posted its earnings results on Thursday, March, 23rd. The biopharmaceutical company reported ($0.84) EPS for the quarter, topping analysts' consensus estimates of ($0.93) by $0.09. The biopharmaceutical company earned $2.49 million during the quarter, compared to analysts' expectations of $1.06 million. When did Aeterna Zentaris' stock split? Shares of Aeterna Zentaris reverse split before market open on Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Aeterna Zentaris own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN) and Washington Prime Group (WPG). What is Aeterna Zentaris' stock symbol? Aeterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS." Who are Aeterna Zentaris' major shareholders? Aeterna Zentaris' stock is owned by many different institutional and retail investors. Top institutional shareholders include Group One Trading L.P. (0.00%) and Susquehanna International Group LLP (0.00%). How do I buy shares of Aeterna Zentaris? Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aeterna Zentaris' stock price today? One share of AEZS stock can currently be purchased for approximately $2.78. How much money does Aeterna Zentaris make? Aeterna Zentaris (NASDAQ:AEZS) has a market capitalization of $13.49 million and generates $5.64 million in revenue each year. The biopharmaceutical company earns $-22,730,000.00 in net income (profit) each year or ($5.01) on an earnings per share basis. How can I contact Aeterna Zentaris? Aeterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The official website for the company is www.zentaris.com. The biopharmaceutical company can be reached via phone at (418) 652-8525, via email at ir@aezsinc.com, or via fax at 418-948-9191. This page (NASDAQ:AEZS) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.